REMARKS

Claims 49-109 are now pending for the Examiner's consideration.

The restriction requirement set forth in the 8/10/2005 Office Action:

On pages 2-4 of the Office Action of 8/10/2005, the Examiner required that the Applicants elect one group from Groups I to VI, wherein Group I consists of claims 49-59 and 96, Group II consists of claims 60-78 and 96-99, Group III consists of claims 79-86, Group IV (unintentionally written as Group VI on page 2 of the Office Action) consists of claims 87-96, Group V consists of claims 100-106 and Group VI (unintentionally written as Group IV on page 2 of the Office Action) consists of claims 107 -108 (Applicants believe the Examiner meant claims 107-109 since claim 109 was left out and ungrouped). The Examiner further required that one single species be elected, as set forth on page 2 of the Office Action.

The new restriction requirement as agreed in the 9/14/05 telephone interview:

The undersigned telephoned the Examiner on September 14, 2005 and discussed the restriction requirement with the Examiner. The undersigned proposed and the Examiner agreed to the following new restriction requirement: Group I consists of claims 49-99 (this is the combination of the previous Group I to IV in the 6/10/05 Office Action); Group II consists of claims 100-106 (this was the previous Group V in the 8/10/05 Office Action); Group III consists of claims 107-109 (this was the previous Group VI in the 8/10/05 Office Action) and the Applicants are also to elect one single species, as set forth on page 2 of the 8/10/05 Office Action previously.

Applicants' election:

Applicants herein elect Group I, which consists of claims 49-99, of the new restriction requirement as set forth in the 9/14/05 telephone interview. Applicants further elects species {(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-2-oxo-2,3-dihydro-1H-indol-1-yl}methyl acetate, which is the title compound of Example 2 in the application, page 64 line 1 to line 13. The structure of this compound is the following:

Applicants thank the Examiner for the telephone interview of 9/14/05.

If any fees other than those provided herein are due in connection to this response, please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: September 28, 2005

Ye Hua \
Attorney For Applicants
Registration No. 53,042

Pfizer Inc. Patent Department 10777 Science Center Drive San Diego, California 92121 Phone: (858) 622-3020

Fax: (858) 678-8233